查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438323

全球肺癌诊断市场、市场规模、预测（2024-2030）、产业趋势、份额、成长、考虑、通货膨胀的影响、公司分析

Lung Cancer Diagnostics Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

预计2030年，全球肺癌诊断市场规模将达到约308.4亿美元。在现代医学中，肺癌诊断对于早期发现和个人化治疗至关重要。CT 扫描和 MRI 等先进的影像策略可以帮助识别肿瘤和转移瘤，并有助于分期和治疗计划。生物标记测试，包括基因突变和蛋白质表现分析，可以实现个人化治疗，改善治疗结果，并最大限度地减少副作用。此外，液体活检可以非侵入性地追踪疾病进展和治疗反应。技术和研究的不断进步不断改善肺癌诊断，有望提高存活率和生活水平。

全球肺癌诊断市场规模预计在预测期间（2024-2030年）复合年增长率为7.23%。

全球肺癌发生率的上升增加了对更好的肺癌诊断的需求。根据Lung Cancer Research Foundation的数据，吸烟是迄今为止肺癌的危险因素，占肺癌死亡人数的 80%。同时，从不吸烟的人占肺癌死亡人数的其余20%。早期检测技术，包括影像技术和生物标记测试，可以改善患者的治疗结果。随着医疗保健系统优先考虑筛检计画和诊断设备，全球肺癌诊断市场正在意外扩大。增加对研究、先进技术和客製化治疗方法的投资将有助于加强对流行疾病的应对。

多模式诊断方法的采用正在彻底改变全球肺癌诊断市场。透过整合 CT、PET 和 MRI 等多种影像方式以及分子生物学/遗传分析，临床医生可以更广泛地了解肿瘤特征和分期。这种方法补充了预后和治疗计划的准确性，推动了癌症诊断市场的成长。随着早期检测和个人化医疗的重要性被认识，对多模式诊断解决方案的需求持续增长，并正在塑造肺癌诊断的格局。因此，2023年全球肺癌诊断市场规模为189.2亿美元。

北美肺癌诊断市场正在显着扩大。这是由新技术和弹性医疗基础设施的采用所推动的。作为创新的灯塔，我们正在製定卓越诊断的标准并刺激全球需求。此外，正在进行的研究和改进活动，特别是在癌症的早期检测方面，有望改善全球肺癌诊断和筛检市场，在预防这种全球流行疾病方面发挥关键作用。我们正在加强它。

全球肺癌诊断市场最重要的领域之一是影像学检测。

影像检查处于全球肺癌诊断市场的前沿。这是因为它对于肿瘤的早期发现和准确评估起着至关重要的作用。电脑断层扫描 (CT)、正子断层扫描 (PET) 和磁振造影 (MRI) 等技术可以帮助识别肺组织，从而帮助定位肿瘤、分期疾病并製定治疗计划。提供可视化。其非侵入性和早期发现异常的能力使其得到认可。由于不断提高分辨率和特异性的技术进步，诊断成像已成为肺癌诊断的关键。这巩固了其作为世界市场主要部门的地位。

非小细胞肺癌是全球肺癌诊断市场最重要的组成部分之一。

非小细胞肺癌（NSCLC）在全球肺癌诊断市场中占有重要地位。这是因为其高发病率和多种治疗选择。NSCLC 极大地推动了诊断评估的需求，包括影像学、生物标记评估和组织病理学。由于其异质性，需要准确的预后和分期来选择最高品质的治疗，从而刺激诊断技术的创新。此外，针对特定 NSCLC 亚型的核心疗法和免疫疗法的进展进一步强调了正确诊断的重要性。由于非小细胞肺癌持续为医疗保健带来重大负担，其诊断阶段仍然是全球肺癌诊断市场的基石。

本报告研究了全球肺癌诊断市场，并对市场成长驱动因素和挑战以及细分市场、地区和公司进行了全面分析。

目录

第一章简介

第二章 研究内容及研究方法

第三章执行摘要

第四章市场动态

  • 增长动力
  • 任务

第五章 全球肺癌诊断市场

第六章市场份额-全球肺癌诊断分析

  • 按诊断测试类型
  • 按癌症类型
  • 按最终用户
  • 按国家

第七章诊断测试类型—全球肺癌诊断市场

  • 影像学检查
  • 活检
  • 痰液细胞学检查
  • 分子检测
  • 其他

第八章癌症类型－全球肺癌诊断市场

  • 非小细胞肺癌
  • 小细胞肺癌

第九章最终用户-全球肺癌诊断市场

  • 医院相关研究所
  • 独立诊断实验室
  • 影像诊断中心
  • 癌症研究所
  • 其他

第十章国家-全球肺癌诊断市场

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 泰国
    • 马来西亚
    • 印度尼西亚
    • 澳大利亚
    • 纽西兰
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第十一章波特五力分析-全球肺癌诊断市场

第十二章 SWOT 分析-全球肺癌诊断市场

第十三章公司分析-全球肺癌诊断市场

  • llumina
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc
  • QIAGEN N.V.
  • Roche Holding AG.
  • Sanofi S.A.
  • Agilent Technologies
  • bioMerieux

Global Lung Cancer Diagnostics Market is predicted to be valued at around US$ 30.84 Billion by 2030, according to Renub Research. In modern-day healthcare, lung cancer diagnostics are pivotal in early detection and personalized treatment. Advanced imaging strategies like CT scans and MRI permit particular identification of tumors and metastases, assisting in staging and treatment planning. Biomarker testing, inclusive of genetic mutations and protein expression analysis, allows for centered remedies tailor-made to their patients, improving results and minimizing side effects. Further, liquid biopsies offer a non-invasive tracking of disease progression and remedy responses. With non-stop improvements in technology and research, lung cancer diagnostics continue to conform, offering a want for improved survival rates and standard of life.

Global Lung Cancer Diagnostics Market is predicted to increase at a CAGR of 7.23% during the projection period (2024 to 2030)

The demand for superior lung cancer diagnostics has improved because of the rising prevalence of the disease globally. According to the Lung Cancer Research Foundation, smoking is the dominating risk element for lung cancer, accounting for 80% of lung cancer deaths. In comparison, individuals who've in no way smoked account for the remaining 20% of lung cancer deaths. Early detection techniques enhance patient outcomes, including imaging technology and biomarker testing. The global lung cancer diagnostics market is expanding unexpectedly as healthcare systems prioritize screening programs and access to diagnostic equipment. Increased investments in studies, progressive technology, and customized remedy approaches fuel an increase in coping with prevailing diseases.

Adopting multimodal diagnostic procedures is revolutionizing the global lung cancer diagnostics market. Clinicians gain broad insights into tumor characteristics and staging by integrating diverse imaging modalities like CT, PET, and MRI alongside molecular and genetic analyses. This approach complements accuracy in prognosis and treatment planning, driving the growth of the cancer diagnostics market. With increasing recognition of the importance of early detection and personalized medicinal drugs, the demand for multimodal diagnostic solutions continues to push upward, shaping the landscape of lung cancer diagnostics worldwide. Hence, the global lung cancer diagnostics market was US$ 18.92 Billion in 2023.

The North America lung cancer diagnostic market has witnessed considerable expansion. This is fueled by adopting contemporary technology and a resilient healthcare infrastructure. As a beacon of innovation, it sets standards for diagnostic excellence, spurring worldwide demand. Moreover, ongoing studies and improvement endeavors, specifically in early cancer detection, promise to elevate the lung cancer diagnostic and screening market worldwide, reinforcing its pivotal role in preventing this pervasive sickness worldwide.

One of the most critical areas of the lung cancer diagnostics market worldwide is imaging tests

By diagnosis test type, the global lung cancer diagnostics market is fragmented into Imaging Tests, Biopsy, Sputum Cytology, Molecular Tests, and Others. Imaging tests stand among the forefront sections of the global lung cancer diagnostics market. This is due to their pivotal function in early detection and correct assessment of tumors. Technologies like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) offer specified visualization of lung tissue, helping in tumor localization, staging, and remedy planning. Their non-invasive nature and capability to stumble on abnormalities at early phases contribute to their recognition. Imaging assessments are vital in lung cancer diagnosis, thanks to non-stop technological improvements that enhance resolution and specificity. This has solidified their function as a leading section in the worldwide market.

Non-Small Cell Lung Cancer is among the most significant elements in the global lung cancer diagnostics market

The global lung cancer diagnostics market is split by cancer type into non-small and small-cell lung cancer. Non-Small Cell Lung Cancer (NSCLC) holds one of the prominent positions in the global lung cancer diagnostics market. This is due to its high incidence and numerous treatment alternatives. NSCLC drives considerable demand for diagnostic assessments, which include imaging, biomarker evaluation, and histopathology. Its heterogeneous nature necessitates a precise prognosis and staging for top-quality remedy choice, spurring innovation in diagnostic technology. Moreover, advancements in centered treatments and immunotherapies tailor-made to particular NSCLC subtypes further underscore the importance of correct diagnosis. As NSCLC continues to pose a substantial healthcare burden, its diagnostic stage remains a cornerstone of the global lung cancer diagnostics market.

Hospital Associated Labs are integral to the global lung cancer diagnostics market

By end-user, the global lung cancer diagnostics market is categorized into Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others. Hospital Associated Labs is one of the most used in the global lung cancer diagnostics market. This is due to their accessibility and comprehensive services. Situated in healthcare centers, these labs offer short turnaround times for diagnostic tests, including imaging, biopsies, and molecular analyses. Their close collaboration with clinicians facilitates seamless patient care, making them a preferred choice for accurate and well-timed lung cancer analysis and treatment planning.

United States may continue to maintain its lead in the global market for lung cancer diagnostics

By country, the global lung cancer diagnostics market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, the Netherlands, and Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand), Latin America (Brazil, Mexico, and Argentina), Middle East & Africa (South Africa, Saudi Arabia, and the UAE). The United States might stay dominant in the global lung cancer diagnostics market. This is pushed by the increasing occurrence of neurological disorders, contributing to improving the area's lung cancer diagnostics market.

For example, in line with a record by the American Society of Clinical Oncology (ASCO) in 2023, 81% of all lung cancer diagnoses in the United States were non-small cell lung cancers (NSCLC). Moreover, the United States has a sturdy healthcare system with advanced diagnostic tools, most lung cancer cases, and a focus on early detection and customized medication. It invests closely in R&D, propelling innovation and setting global lung cancer diagnosis standards.

Key Players

The global lung cancer diagnostics market comprises of leading companies like llumina, Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG., Sanofi S.A., Agilent Technologies, and bioMerieux.

In October 2023 - DELFI Diagnostics recently announced the launch of FirstLook Lung, a blood-based test that provides a new and more accessible way to detect lung cancer. This test offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT) with a negative predictive value (NPV) of 99.7 percent.

Diagnosis Test Type - Market breakup in 5 viewpoints:

1. Imaging Test

2. Biopsy

3. Sputum Cytology

4. Molecular Test

5. Others

Cancer Type - Market breakup in 2 viewpoints:

1. Non- Small Cell Lung Cancer

2. Small Cell Lung Cancer

End-User - Market breakup in 5 viewpoints:

1. Hospital Associated Labs

2. Independent Diagnostic Laboratories

3. Diagnostic Imaging Centers

4. Cancer Research Institutes

5. Others

Country - Market breakup in 25 Countries:

1. North America

  • 1.1 United States
  • 1.2 Canada

2. Europe

  • 2.1 France
  • 2.2 Germany
  • 2.3 Italy
  • 2.4 Spain
  • 2.5 United Kingdom
  • 2.6 Belgium
  • 2.7 Netherlands
  • 2.8 Turkey

3. Asia Pacific

  • 3.1 China
  • 3.2 Japan
  • 3.3 India
  • 3.4 South Korea
  • 3.5 Thailand
  • 3.6 Malaysia
  • 3.7 Indonesia
  • 3.8 Australia
  • 3.9 New Zealand

4. Latin America

  • 4.1 Brazil
  • 4.2 Mexico
  • 4.3 Argentina

5. Middle East & Africa

  • 5.1 Saudi Arabia
  • 5.2 UAE
  • 5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

  • Overview
  • Recent Development
  • Revenue Analysis

Company Analysis:

1. llumina

2. Abbott Laboratories

3. Thermo Fisher Scientific, Inc.

4. QIAGEN N.V.

5. Roche Holding AG.

6. Sanofi S.A.

7. Agilent Technologies

8. bioMerieux.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Lung Cancer Diagnostics Market

6. Market Share - Global Lung Cancer Diagnostics Analysis

  • 6.1 By Diagnosis Test Type
  • 6.2 By Cancer Type
  • 6.3 By EndUsers
  • 6.4 By Country

7. Diagnosis Test Type - Global Lung Cancer Diagnostics Market

  • 7.1 Imaging Test
  • 7.2 Biopsy
  • 7.3 Sputum Cytology
  • 7.4 Molecular Test
  • 7.5 Others

8. Cancer Type - Global Lung Cancer Diagnostics Market

  • 8.1 Non- Small Cell Lung Cancer
  • 8.2 Small Cell Lung Cancer

9. End-User - Global Lung Cancer Diagnostics Market

  • 9.1 Hospital Associated Labs
  • 9.2 Independent Diagnostic Laboratories
  • 9.3 Diagnostic Imaging Centers
  • 9.4 Cancer Research Institutes
  • 9.5 Others

10. Country - Global Lung Cancer Diagnostics Market

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa

11. Porter's Five Analysis - Global Lung Cancer Diagnostics Market

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis - Global Lung Cancer Diagnostics Market

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Company Analysis - Global Lung Cancer Diagnostics Market

  • 13.1 llumina
    • 13.1.1 Overviews
    • 13.1.2 Recent Development
    • 13.1.3 Revenues
  • 13.2 Abbott Laboratories
    • 13.2.1 Overviews
    • 13.2.2 Recent Development
    • 13.2.3 Revenues
  • 13.3 Thermo Fisher Scientific, Inc
    • 13.3.1 Overviews
    • 13.3.2 Recent Development
    • 13.3.3 Revenues
  • 13.4 QIAGEN N.V.
    • 13.4.1 Overviews
    • 13.4.2 Recent Development
    • 13.4.3 Revenues
  • 13.5 Roche Holding AG.
    • 13.5.1 Overviews
    • 13.5.2 Recent Development
    • 13.5.3 Revenues
  • 13.6 Sanofi S.A.
    • 13.6.1 Overview
    • 13.6.2 Recent Development
    • 13.6.3 Financial Insights
  • 13.7 Agilent Technologies
    • 13.7.1 Overview
    • 13.7.2 Recent Development
    • 13.7.3 Financial Insights
  • 13.8 bioMerieux
    • 13.8.1 Overview
    • 13.8.2 Recent Development
    • 13.8.3 Financial Insights

List of Figures

  • Figure-01: Global - Lung Cancer Diagnostics Market (Billion US$), 2019 - 2023
  • Figure-02: Global - Forecast for Lung Cancer Diagnostics Market (Billion US$), 2024 - 2030
  • Figure-03: Diagnosis Test Type - Imaging Test Market (Million US$), 2019 - 2023
  • Figure-04: Diagnosis Test Type - Forecast for Imaging Test Market (Million US$), 2024 - 2030
  • Figure-05: Diagnosis Test Type - Biopsy Market (Million US$), 2019 - 2023
  • Figure-06: Diagnosis Test Type - Forecast for Biopsy Market (Million US$), 2024 - 2030
  • Figure-07: Diagnosis Test Type - Sputum Cytology Market (Million US$), 2019 - 2023
  • Figure-08: Diagnosis Test Type - Forecast for Sputum Cytology Market (Million US$), 2024 - 2030
  • Figure-09: Diagnosis Test Type - Molecular Test Market (Million US$), 2019 - 2023
  • Figure-10: Diagnosis Test Type - Forecast for Molecular Test Market (Million US$), 2024 - 2030
  • Figure-11: Diagnosis Test Type - Others Market (Million US$), 2019 - 2023
  • Figure-12: Diagnosis Test Type - Forecast for Others Market (Million US$), 2024 - 2030
  • Figure-13: Cancer Type - Non- Small Cell Lung Cancer Market (Million US$), 2019 - 2023
  • Figure-14: Cancer Type - Forecast for Non- Small Cell Lung Cancer Market (Million US$), 2024 - 2030
  • Figure-15: Cancer Type - Small Cell Lung Cancer Market (Million US$), 2019 - 2023
  • Figure-16: Cancer Type - Forecast for Small Cell Lung Cancer Market (Million US$), 2024 - 2030
  • Figure-17: End-User - Hospital Associated Labs Market (Million US$), 2019 - 2023
  • Figure-18: End-User - Forecast for Hospital Associated Labs Market (Million US$), 2024 - 2030
  • Figure-19: End-User - Independent Diagnostic Laboratories Market (Million US$), 2019 - 2023
  • Figure-20: End-User - Forecast for Independent Diagnostic Laboratories Market (Million US$), 2024 - 2030
  • Figure-21: End-User - Diagnostic Imaging Centers Market (Million US$), 2019 - 2023
  • Figure-22: End-User - Forecast for Diagnostic Imaging Centers Market (Million US$), 2024 - 2030
  • Figure-23: End-User - Cancer Research Institutes Market (Million US$), 2019 - 2023
  • Figure-24: End-User - Forecast for Cancer Research Institutes Market (Million US$), 2024 - 2030
  • Figure-25: End-User - Others Market (Million US$), 2019 - 2023
  • Figure-26: End-User - Forecast for Others Market (Million US$), 2024 - 2030
  • Figure-27: United States - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-28: United States - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-29: Canada - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-30: Canada - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-31: France - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-32: France - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-33: Germany - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-34: Germany - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-35: Italy - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-36: Italy - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-37: Spain - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-38: Spain - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-39: United Kingdom - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-40: United Kingdom - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-41: Belgium - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-42: Belgium - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-43: Netherlands - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-44: Netherlands - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-45: Turkey - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-46: Turkey - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-47: China - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-48: China - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-49: Japan - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-50: Japan - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-51: India - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-52: India - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-53: South Korea - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-54: South Korea - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-55: Thailand - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-56: Thailand - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-57: Malaysia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-58: Malaysia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-59: Indonesia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-60: Indonesia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-61: Australia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-62: Australia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-63: New Zealand - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-64: New Zealand - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-65: Brazil - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-66: Brazil - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-67: Mexico - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-68: Mexico - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-69: Argentina - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-70: Argentina - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-71: Saudi Arabia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-72: Saudi Arabia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-73: UAE - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-74: UAE - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-75: South Africa - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-76: South Africa - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-77: llumina - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-78: llumina - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-79: Abbott Laboratories - Global Revenue (Million US$), 2019 - 2023
  • Figure-80: Abbott Laboratories - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-81: Thermo Fisher Scientific, Inc - Global Revenue (Million US$), 2019 - 2023
  • Figure-82: Thermo Fisher Scientific, Inc - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-83: QIAGEN N.V. - Global Revenue (Million US$), 2019 - 2023
  • Figure-84: QIAGEN N.V. - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-85: Roche Holding AG. - Global Revenue (Million US$), 2019 - 2023
  • Figure-86: Roche Holding AG. - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-87: Sanofi S.A. - Global Revenue (Million US$), 2019 - 2023
  • Figure-88: Sanofi S.A. - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-89: Agilent Technologies - Global Revenue (Million US$), 2019 - 2023
  • Figure-90: Agilent Technologies - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-91: bioMerieux - Global Revenue (Million US$), 2019 - 2023
  • Figure-92: bioMerieux - Forecast for Global Revenue (Million US$), 2024 - 2030

List of Tables

  • Table-01: Global - Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2019 - 2023
  • Table-02: Global - Forecast for Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2024 - 2030
  • Table-03: Global -Lung Cancer Diagnostics Market Share by Cancer Type (Percent), 2019 - 2023
  • Table-04: Global - Forecast for Lung Cancer Diagnostics Market Share by Cancer Type (Percent), 2024 - 2030
  • Table-05: Global - Lung Cancer Diagnostics Market Share by End-User (Percent), 2019 - 2023
  • Table-06: Global - Forecast for Lung Cancer Diagnostics Market Share by End-User (Percent), 2024 - 2030
  • Table-07: Global - Lung Cancer Diagnostics Market Share by Region (Percent), 2019 - 2023
  • Table-08: Global - Forecast for Lung Cancer Diagnostics Market Share by Region (Percent), 2024 - 2030